Potential sources of interference with the highly sensitive detection and quantification of alpha-synuclein seeds by qRT-QuIC.
(q)RT-QuIC
Parkinson’s disease
aggregation
alpha-synuclein
biomarker
seeding
Journal
FEBS open bio
ISSN: 2211-5463
Titre abrégé: FEBS Open Bio
Pays: England
ID NLM: 101580716
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
06
11
2019
revised:
10
02
2020
accepted:
16
03
2020
pubmed:
20
3
2020
medline:
10
7
2021
entrez:
20
3
2020
Statut:
ppublish
Résumé
Parkinson's disease (PD) is a progressive neurodegenerative disease which is histologically characterized by loss of dopaminergic neurons in the substantia nigra and deposition of aggregated alpha-synuclein (aSyn) in the brain. The detection of aSyn in well accessible fluids has been one of the central approaches in the development of biomarkers for PD. Recently, real-time quaking-induced conversion (RT-QuIC) has been successfully adapted for use with aSyn seeds. Here, we systematically analysed parameters potentially impacting the reliability of this assay by using quantitative real-time quaking-induced conversion (qRT-QuIC) with in vitro-formed aSyn seeds. Seeds diluted in cerebrospinal fluid (CSF) accelerated the seeding reaction and slightly increased the sensitivity without affecting specificity. Repeated freeze-thaw cycles decreased the apparent lag times of seeds diluted in ddH
Identifiants
pubmed: 32190992
doi: 10.1002/2211-5463.12844
pmc: PMC7193167
doi:
Substances chimiques
Biomarkers
0
alpha-Synuclein
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
883-893Informations de copyright
© 2020 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Références
JAMA Neurol. 2017 Feb 1;74(2):163-172
pubmed: 27918765
Nat Methods. 2007 Aug;4(8):645-50
pubmed: 17643109
J Neuropathol Exp Neurol. 2015 Sep;74(9):924-33
pubmed: 26247395
Neurosci Lett. 2013 Jan 4;532:44-8
pubmed: 23149132
ACS Chem Neurosci. 2019 Mar 20;10(3):1649-1659
pubmed: 30605594
Brain. 1991 Oct;114 ( Pt 5):2283-301
pubmed: 1933245
Mol Neurodegener. 2016 Jan 19;11:7
pubmed: 26782965
Biochim Biophys Acta. 2015 Sep;1850(9):1884-90
pubmed: 26028294
Ann Clin Transl Neurol. 2016 Aug 28;3(10):812-818
pubmed: 27752516
Biochem Biophys Res Commun. 2007 Jun 22;358(1):104-10
pubmed: 17475220
Neurosci Lett. 2015 Jul 10;599:115-9
pubmed: 25998655
Acta Neuropathol Commun. 2013 Aug 02;1:44
pubmed: 24252329
Biochem Biophys Res Commun. 2006 Oct 13;349(1):162-6
pubmed: 16930553
Nat Methods. 2008 Mar;5(3):211-2
pubmed: 18309304
Neurology. 2004 May 25;62(10):1835-8
pubmed: 15159488
FASEB J. 2006 Mar;20(3):419-25
pubmed: 16507759
J Biol Chem. 2004 May 21;279(21):21966-75
pubmed: 15028717
J Biol Chem. 2012 Jun 15;287(25):21530-40
pubmed: 22549788
Neurodegener Dis. 2008;5(2):55-9
pubmed: 18182779
Protein Sci. 2012 Jul;21(7):911-7
pubmed: 22573613
Biophys J. 2013 Oct 1;105(7):1700-9
pubmed: 24094411
FASEB J. 2011 Dec;25(12):4127-37
pubmed: 21865317
Neuron. 2003 Sep 11;39(6):889-909
pubmed: 12971891
Acta Neuropathol. 2016 Jun;131(6):935-49
pubmed: 27021906
Acta Neuropathol Commun. 2018 Feb 9;6(1):7
pubmed: 29422107
Biochim Biophys Acta Biomembr. 2018 Jan 27;:
pubmed: 29366673
Ann Neurol. 2004 Oct;56(4):532-9
pubmed: 15389895